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(95%CI 1.44, 48.35) for patients with the VKORC1 TT (rs9923231) genotype com-
pared with other genotypes. The mean cost of health care attributable to warfarin 
therapy was a392. The management of warfarin-related adverse events contributed to 
53% of the overall cost. The mean costs for those who experienced an adverse event 
was a884 (95%CI, 554, 1837) compared with a178 (95%CI, 164, 192) for the 179 
patients who did not. CONCLUSIONS: Our analysis is the ﬁ rst to demonstrate a 
signiﬁ cant association between VKORC1 variant genotype and hospitalization.
Although no independent effect on total cost was evident, carriers of VKORC1 TT 
were eight times more likely to be hospitalized due to adverse events.
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OBJECTIVES: To estimate the uncertainty regarding adjuvant treatment selection for 
postmenopausal women with early stage oestrogen-receptor positive breast cancer 
when pre-treatment CYP2D6 pharmacogenetic testing is considered as an option. In
addition, the expected value of partial perfect information (EVPPI) was estimated for 
different parameter sets to inform research prioritisation. METHODS: A decision 
analytic model estimated lifetime costs and quality adjusted life years (QALYs) for
four comparators: 5 years of tamoxifen; 5 years of an aromatase inhibitor (AI);
CYP2D6 test and treat wt/wt genotypes with tamoxifen and other genotypes with an 
AI; CYP2D6 test and treat wt/wt and wt/*4 genotypes with tamoxifen and *4/*4 
genotypes with an AI. No trial data for CYP2D6 contingent treatment pathways were 
identiﬁ ed. Trial data comparing tamoxifen to anastrozole was therefore synthesised 
with observational data linking CYP2D6 genotype to recurrence in patients receiving
tamoxifen. Estimates of the EVPPI were derived by attaching distributions to input
parameters and using two-level Monte Carlo simulation. EVPPI estimates were gener-
ated for parameters describing the efﬁ cacy of tamoxifen and anastrozole; parameters 
describing genotype-speciﬁ c tamoxifen efﬁ cacy; genotype prevalence; utility weights
and health state costs. RESULTS: The strategy of CYP2D6 test and treat wt/wt
patients with tamoxifen and all others with an AI maximised expected net beneﬁ t 
assuming a decision threshold of a30,000/QALY, and had an incremental cost-effec-
tiveness ratio of a14,133/QALY. However, this maximised net beneﬁ t with only 61% 
certainty. This substantial decision uncertainty led to an expected value of perfect
information estimate of a84 million. The EVPPI estimate for parameters describing 
genotype-speciﬁ c tamoxifen efﬁ cacy was a57 million. Estimates for other parameter
groups were low. CONCLUSIONS: Further CYP2D6 genotyping studies amongst
patients receiving tamoxifen should be prioritised. Expected value of sample informa-
tion analysis could be used to establish the cost-effectiveness and optimal design of 
this primary research.
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OBJECTIVES: Recent studies have reported that women receiving adjuvant tamoxifen
with CYP2D6 poor metabolizer genotype have a higher risk of breast cancer recur-
rence than women without poor metabolizer genotype. The objective of this study 
was to evaluate pharmacogenetic testing for CYP2D6 variants as an approach to help 
clinicians identify postmenopausal women that would be better candidates for alterna-
tive therapies. METHODS: We developed a decision-analytic lifetime Markov model 
consisting of 6 health states and assessed a hypothetical cohort of 64-year old women
with ER breast cancer receiving tamoxifen. We assumed women who were poor
metabolizers would be switched to anastrazole. The incidence of local regional relapse, 
metastasis, and breast cancer death were obtained from the 2005 ATAC trial. The 
hazard ratio for disease recurrence in poor vs. extensive metabolizers was derived from 
a recent study by Goetz et al. Cost, utilities and background mortality rates were 
obtained from the published literature or publicly available sources. One-way sensitiv-
ity analyses and scenario analyses were conducted to evaluate uncertainty. RESULTS:
Projected disease free survival at 5 years was 81.4% for tamoxifen and 83.3% for
anastrozole, compared to 81.0% and 83.8% in the ATAC trial. Treatment with
tamoxifen resulted in 11.95 QALYs, anastrozole 12.15 QALYs, and CYP2D6-guided 
treatment 12.19 QALYs. The testing strategy resulted in the greatest QALYs with a 
hazard ratio for recurrence in CYP2D6 variant versus wild-type patients of 1.66 or 
higher, or variant prevalence greater than 20%. CONCLUSIONS: Genetic testing for 
CYP2D6 status in postmenopausal women taking adjuvant tamoxifen may lead to 
clinically meaningful improvements in survival and quality of life. Evaluation of the 
relative impact of drug-related adverse events, validation of association studies, and
assessment in ethnically diverse populations are needed before widespread testing can 
be recommended.
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ON THE ISSUE OF UTILITY MULTIPLICATION: A REVISIT
Fu AZ
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OBJECTIVE: Several estimators exist when average utility scores are not available for
patient populations with multiple disease conditions. The multiplicative estimator is 
a widespread choice among them. This study is to empirically test the accuracy of the
multiplicative estimator and compare it with other estimators. METHODS: Using the
pooled Medical Expenditure Panel Survey (MEPS) 2001 and 2003 data, a sample of 
40,846 adults with EQ-5D preference-based index scores were categorized into 238
disease condition categories. Due to the MEPS sampling property, co-morbid pair 
categories with less than 100 individuals were excluded, which left us with 760 co-
morbid pairs in total. The study focus was the bias from the estimators to the observed 
mean scores for each co-morbid pair, with the observed scores presumed to be the 
true value. The analyses were conducted using both the raw estimators and the res-
caled (puriﬁ ed) estimators. Regressions and concordance correlation coefﬁ cients were 
also used to evaluate the agreement between the estimators and the observed scores.
RESULTS: Using the rescaled approach, the scores estimated by multiplying the 2
mean scores of the corresponding disease conditions on average had a statistically 
signiﬁ cantly larger bias (p  0.0001) from the observed ones (0.043) than simply 
picking the smaller mean of the 2 paired conditions (minimum estimator, bias  0.027). 
However, the multiplicative estimator had less bias than other estimators including 
the additive estimator (bias  0.054), the larger mean (bias  0.077), the average of 
the means (bias  0.052), mean of the condition with smaller sample (bias  0.053). 
Results produced by other analyses, including using the raw scores, all favored the 
minimum estimator than the multiplicative estimator. CONCLUSIONS: Multiplica-
tion is not a good estimate when the average utility score for patients with 2 disease
conditions is not readily available. The lower of the 2 utility scores had the least error 
among those estimators that we compared.
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OBJECTIVE: To measure whether public values for health vary with the age of the
affected individual. METHODS: We ﬁ elded a discrete choice experiment via the
internet in December 2007 to measure preferences for different attributes of inﬂ uenza-
related health states: length of episode (days of illness), severity of illness (workdays
lost), age of hypothetical affected individual (range: 1–85 yrs), and time-tradeoff 
amounts (1day – 2 yrs). We also collected data on socio-demographic characteristics 
and experience with inﬂ uenza illness. Respondents were 18 years and older and
matched to reﬂ ect characteristics of the general US adult population (n  1012). 
Response rate was 67%. Respondents were presented with pairs of illness proﬁ les for
a hypothetical individual and indicated the proﬁ le they preferred. Each respondent
answered 8 discrete choice questions. A full factorial design was used. Discrete choice
analysis using generalized estimating equations was used to evaluate the relative value
of different attributes in the illness proﬁ le while controlling for socio-demographic 
characteristics and inﬂ uenza experience. RESULTS: As measured by time-tradeoff 
amounts, respondents preferred shorter inﬂ uenza episodes (total length) but did not
signiﬁ cantly prefer fewer workdays lost if episode length was held constant. Respon-
dents preferred to avert uncomplicated illness in very young children (1 year old child:
odds ratio  2.35, p  0.05; 3 year old child: odds ratio  3.21, p  0.01) and older
adults (85 year old: odds ratio  2.41, p  0.05) compared to a 35 year old adult. For 
an inﬂ uenza-related hospitalization, respondents preferred to avert illness in very 
young children (1 year old child: odds ratio  2.86, p  0.01) compared to a 35 year 
old adult. CONCLUSIONS: Approaches that assume values for illnesses do not vary
with the age of a patient may bias economic analyses that use these values. If patient
age is likely to affect valuations, then age should be included as an attribute in the
valuation exercise.
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OBJECTIVE: Do people weigh gains in life years differently when patients differ in 
age (but not in life expectancy), life expectancy (but not in age) or QOL (but not age 
or life expectancy)? METHODS: Trade off questions wer developed searching for
indifference between giving healthy life years to patients with different ages, prognoses 
and quality of life. Data come from 46 heart failure patients, 60 healthy controls and 
180 students. For age, as well as prognosis and QOL, six comparative sets were 
developed. Each respondent answered two questions of each set and two combina-
tion-questions. Ordered logistic regression was used in combination with conditional 
linear regression for “extreme” answers. Answers are “extreme” when, for example, 
one extra life year in a young patient is preferred to 10 in an old patient or when
respondents can’t choose. RESULTS: More than 40% of the answers are “extreme”.
